Alk-Abelló A/S
🇩🇰Denmark
Impact of AIT on Allergic Rhinitis and Asthma
- First Posted Date
- 2019-10-14
- Last Posted Date
- 2021-06-02
- Lead Sponsor
- ALK-Abelló A/S
- Target Recruit Count
- 92048
- Registration Number
- NCT04125888
- Locations
- 🇩🇰
ALK Abelló, Hørsholm, Denmark
N.I.S of AIT in Adult Patients With House Dust Mite Allergy in Real Practice in France
- First Posted Date
- 2018-11-20
- Last Posted Date
- 2021-05-17
- Lead Sponsor
- ALK-Abelló A/S
- Target Recruit Count
- 1508
- Registration Number
- NCT03746860
- Locations
- 🇫🇷
Hôpital Arnaud de Villeneuve, Montpellier, France
Mite Asthma Pediatric Immunotherapy Trial
- First Posted Date
- 2018-08-31
- Last Posted Date
- 2023-10-19
- Lead Sponsor
- ALK-Abelló A/S
- Target Recruit Count
- 533
- Registration Number
- NCT03654976
- Locations
- 🇧🇬
Alitera-Med-Medical Center EOOD, Sofia, Bulgaria
🇵🇱Specjalistyczna Praktyka Lekarska, Katowice, Poland
🇪🇸Hospital Universitario Vall d'Hebrón, Barcelona, Spain
A Dose-response Evaluation of the SQ Tree SLIT-tablet Using an Environmental Exposure Chamber
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2015-06-25
- Last Posted Date
- 2017-01-19
- Lead Sponsor
- ALK-Abelló A/S
- Target Recruit Count
- 219
- Registration Number
- NCT02481856
- Locations
- 🇨🇦
Inflamax Research Inc., Mississauga, Ontario, Canada
Molecular and Cellular Mechanism in Rhinitis Allergic Patients Treated With GRAZAX®
- First Posted Date
- 2015-05-08
- Last Posted Date
- 2018-01-17
- Lead Sponsor
- ALK-Abelló A/S
- Target Recruit Count
- 58
- Registration Number
- NCT02437786
- Locations
- 🇪🇸
Hospital Universitario de La Princesa, Madrid, Spain
Safety Study of MK-3641 and MK-7243 Co-administered in Adult Participants With Ragweed and Grass Pollen Induced Allergic Rhinitis (P08607, MK-3641-006)
- First Posted Date
- 2014-10-03
- Last Posted Date
- 2017-03-03
- Lead Sponsor
- ALK-Abelló A/S
- Target Recruit Count
- 102
- Registration Number
- NCT02256553
Evaluation of the Efficacy and Safety of AVANZ® Phleum Pratense in Grass Pollen-induced Allergic Rhinitis During Controlled Exposure in an Environmental Challenge Chamber
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2014-06-18
- Last Posted Date
- 2016-01-26
- Lead Sponsor
- ALK-Abelló A/S
- Target Recruit Count
- 140
- Registration Number
- NCT02166268
- Locations
- 🇩🇪
Fraunhofer Institute, Hannover, Germany
An Open Trial to Assess the Tolerability of AVANZ® Cupressus Immunotherapy
- First Posted Date
- 2014-02-24
- Last Posted Date
- 2015-01-06
- Lead Sponsor
- ALK-Abelló A/S
- Target Recruit Count
- 52
- Registration Number
- NCT02069535
- Locations
- 🇪🇸
Hospital Clinico Universitario San Carlos, Madrid, Spain
An Open Trial to Assess the Tolerability of AVANZ® Salsola Immunotherapy
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2014-02-19
- Last Posted Date
- 2015-01-14
- Lead Sponsor
- ALK-Abelló A/S
- Target Recruit Count
- 51
- Registration Number
- NCT02065856
- Locations
- 🇪🇸
Hospital General Universitario de Alicante, Alicante, Spain
Molecular and Cellular Mechanism in the Course of Immunotherapy With a Phleum Pratense Oral Lyophilisate
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2013-05-15
- Last Posted Date
- 2017-06-28
- Lead Sponsor
- ALK-Abelló A/S
- Target Recruit Count
- 51
- Registration Number
- NCT01854736
- Locations
- 🇪🇸
Hospital Universitario de La Princesa, Madrid, Spain
🇪🇸Hospital Clínico Universitario San Carlos, Madrid, Spain
© Copyright 2024. All Rights Reserved by MedPath